Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
vaccine
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02772003CT.gov DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rocakinogene Sifuplasmid (this asset) | National Cancer Institute (NCI) | P1 | CC · 43 |
| Meperidine | Erasme University Hospital | P4 | BB |
| Midazolam | Erasme University Hospital | P4 | BB |
| Orlistat | St. Louis University | P4 | BB |
| Ursodeoxycholic Acid | West China Hospital | P4 | BB |
| Entecavir | Cttq | P4 | BB |
| Diammonium Glycyrrhizinate | Cttq | P4 | BB |
| Magnesium Isoglycyrrhizinate | Cttq | P4 | BB |
| Total Glucosides Of Paeony | West China Hospital | P4 | BB |
+23 more in the Hepatitis cohort
Other indications for Rocakinogene Sifuplasmid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis C Virus Infection | — | P1 | CC · 43 |
| Hepatocellular Carcinoma | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rocakinogene Sifuplasmid in Hepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rocakinogene-sifuplasmid-hepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →